Edition:
India

People: Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

48.88USD
11:08pm IST
Change (% chg)

$1.85 (+3.93%)
Prev Close
$47.03
Open
$47.50
Day's High
$49.55
Day's Low
$47.50
Volume
89,369
Avg. Vol
195,724
52-wk High
$67.86
52-wk Low
$29.17

Doogan, Declan 

Dr. Declan Doogan, M.D., serves as Independent Chairman of the Board of Biohaven Pharmaceutical Holding Company Limited. Dr. Doogan has served as a director of our Company since its inception in September 2013. Dr. Doogan has served as the chief executive officer and director of Portage Biotech, Inc. (PTGEF: OTCBB) since June 2013, a director of Portage Pharmaceuticals Limited since July 2013, a director of Sosei Group Corporation from June 2007 to June 2018 and a director of Kleo Pharmaceuticals since August 2016. Dr. Doogan has over 30 years of industry experience in both major pharma and biotech. He was the Senior Vice-President and Head of Worldwide Development at Pfizer Inc., or Pfizer, and has held a number of executive positions in Pfizer in the United States, the United Kingdom and Japan. Since leaving Pfizer in 2007, he has been engaged in executive roles in small pharmaceutical companies. Dr. Doogan was chief medical officer and acting chief executive officer of Amarin Corporation plc (AMRN: NASDAQ). He has also been Chief Medical Officer for Prometheus Laboratories, a molecular diagnostics company in San Diego. Dr. Doogan holds a number of board appointments, principally in pharmaceutical companies, and has also held professorships at Harvard School of Public Health, Glasgow University Medical School and Kitasato University (Tokyo). Dr. Doogan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine and holds a Doctorate of Science from the University of Kent in the UK. We believe that Dr. Doogan’s extensive operational experience in the pharmaceutical and biotech industries qualifies him to serve as a member of our Board.

Basic Compensation

Total Annual Compensation, USD 621,360
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 85,000
Fiscal Year Total, USD 706,360

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Declan Doogan

706,360

Vlad Coric

7,854,000

James Engelhart

3,217,070

Kimberly Gentile

2,784,540

Charles Conway

2,792,860

Robert Berman

521,060
As Of  31 Dec 2018